Fat Burning Peptides Market 2026: $2.8B Projected Growth Driven by AOD-9604 & Tesofensine Clinical Data
Title: Fat Burning Peptides Market 2026: $2.8B Projected Growth Driven by AOD-9604 & Tesofensine Clinical Data Abstract (148 words): The fat burning peptides market is projected to reach $2.8 billion by 2026, driven by robust clinical data for AOD-9604 (targeting lipolysis) and Tesofensine (appetite suppression). This growth reflects a shift from generic GLP-1 agonists toward targeted peptide therapeutics. Key product comparisons reveal AOD-9604’s superior safety profile versus Tesofensine’s higher efficacy but stricter regulatory oversight. Market leaders (e.g., Novo Nordisk, Eli Lilly) dominate via FDA-approved GLP-1 analogs, while niche brands focus on AOD-9604 for localized fat loss. Technical advantages include high specificity and low immunogenicity; disadvantages include short half-lives requiring frequent dosing. Industry trends emphasize GMP-certified manufacturing and cold-chain logistics (2-8°C) to maintain peptide stability. Selection criteria prioritize purity (>98% HPLC), third-party COAs, and clinical trial backing. The market’s future hinges on oral delivery innovations and expanded indications beyond obesity.